Klotho CFO granted 2.5M shares in equity award

Klotho Neurosciences, Inc. reported that Chief Financial Officer Jeff LeBlanc acquired 2,500,000 shares of common stock on a grant/award basis.

Accepted by SEC EDGAR 03/06/2026 - 04:12 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Klotho Neurosciences, Inc. reported that Chief Financial Officer Jeff LeBlanc acquired 2,500,000 shares of common stock on a grant/award basis. The shares were received at a price of $0.00 per share as a grant under the company’s Equity Incentive Plan, meaning no cash purchase was involved.

Following this equity award, LeBlanc directly holds 3,420,342 common shares of Klotho Neurosciences. This filing records an increase in his equity-based compensation and ownership stake through the company’s incentive program.

Insider Trade Summary

Grant/Award: 2,500,000 shares

Grant/Award 1 txn

Insider LeBlanc Jeff

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,500,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 3,420,342 shares (Direct)

Footnotes (1)

1. F1. The Reporting person received the shares as a grant under the company's Equity Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KLTO report for CFO Jeff LeBlanc?

Klotho Neurosciences reported that CFO Jeff LeBlanc received a grant of 2,500,000 shares of common stock. The award was issued at $0.00 per share under the company’s Equity Incentive Plan, increasing his directly held ownership stake.

How many KLTO shares does the CFO hold after this Form 4 transaction?

After the reported grant, CFO Jeff LeBlanc directly holds 3,420,342 shares of Klotho Neurosciences common stock. This total reflects the newly awarded 2,500,000-share grant reported in the Form 4 insider transaction filing.

Was cash paid for the 2,500,000 KLTO shares granted to the CFO?

No cash was paid for these shares. The 2,500,000 Klotho Neurosciences shares were granted to CFO Jeff LeBlanc at $0.00 per share as an equity award under the company’s Equity Incentive Plan, rather than an open-market purchase.

What is the transaction code used in the KLTO Form 4 for the CFO grant?

The transaction code is “A,” indicating a grant, award, or other acquisition. This shows the 2,500,000 Klotho Neurosciences common shares were received as an equity award, consistent with the company’s Equity Incentive Plan footnote disclosure.

What type of security did the KLTO CFO receive in this insider filing?

CFO Jeff LeBlanc received Klotho Neurosciences common stock. The Form 4 reports a non-derivative transaction involving 2,500,000 shares of common stock granted under the company’s Equity Incentive Plan, increasing his directly owned share position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBlanc Jeff

(Last) (First) (Middle)

1300 SOUTH BOULEVARD SUITE D

(Street)

CHARLOTTE NC 28203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klotho Neurosciences, Inc. [ KLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		2,500,000	A	(1)	3,420,342	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting person received the shares as a grant under the company's Equity Incentive Plan.

Remarks:

	Jeff LeBlanc	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.